This trial is testing a new cancer drug, ICP-192, on patients with advanced solid tumors and FGFR gene alterations. The trial has two parts, with the first part testing different doses of the drug to see what is safe and effective, and the second part expanding the study to more patients.
5 Primary · 6 Secondary · Reporting Duration: Up to 3 years
Experimental Treatment
45 Total Participants · 1 Treatment Group
Primary Treatment: Drug ICP-192 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: